Cartalax

What it is

Cartalax is associated with the short peptide Ala-Glu-Asp, or AED. It is distinct from the AEDG peptide Epitalon and the AEDP peptide Cortagen, despite inconsistent naming on some commercial pages.

What the laboratory evidence shows

The most relevant studies are cell-culture experiments. AED has increased proliferation in rat chondrocyte cultures and changed the expression or synthesis of chondrogenic markers such as SOX9, aggrecan, type II collagen, and COMP in aging human mesenchymal stem cells. Other experiments reported changes in senescence-associated signaling in cultured chondrocytes. These findings create a cartilage-repair hypothesis; they do not demonstrate repaired human cartilage.

Human evidence

I found one manufacturer-associated Russian report covering an oral Cartalax supplement. It included only ten Cartalax-treated people with knee osteoarthritis and nine controls, alongside separate spinal-disease and osteoporosis groups. Cartalax was added to usual treatment, the report did not describe adequate randomization or blinding, and it found no meaningful radiographic change. I treat the reported symptom improvement as a weak observation, not a clinical efficacy result.

Why clicking is a limited readout

Knee clicking and crepitus can change for reasons other than cartilage structure. A systematic review found crepitus in both pain-free people and people with osteoarthritis. Less clicking is a useful personal movement signal, but it cannot establish new cartilage, structural repair, or a specific mechanism.

Evidence and safety boundary

I did not find a registered Cartalax intervention on ClinicalTrials.gov or adequate human pharmacokinetic, dose-ranging, interaction, or long-term safety data. The public record therefore separates my positive personal outcome from the much weaker general evidence base.

Sources

• National Library of Medicine: Cartalax / Ala-Glu-Asp identity
• Myakisheva et al., rat chondrocyte proliferation, 2023
• Myakisheva et al., chondrogenic markers in aging human mesenchymal stem cells, 2023
• Myakisheva et al., chondrocyte senescence-associated signaling, 2023
• Russian Cartalax supplement report, 2011, pp. 125–129
• Couch et al., knee-crepitus systematic review, 2025
• ClinicalTrials.gov search: Cartalax

Protocol

I used 10 mg per day for ten consecutive days, beginning July 17, 2026 and ending July 26. These are historical details of what I did, not a suggested protocol.

Question

The practical question was whether a short Cartalax run would produce a noticeable change in joint movement, especially at the knees, where I sometimes experienced random clicking sounds.

Observed result

My joints began to feel smoother in motion, particularly at the knees, and the intermittent clicking became less noticeable. The full effect did not appear immediately during the ten dosing days; some of the improvement became clearer after the cycle had ended.

Interpretation

The delayed and persistent pattern makes continued downstream biological activity one possible explanation, but this experiment did not measure pharmacokinetics, inflammation, cartilage, imaging, or any other mechanism. Natural symptom variation, training load, movement mechanics, and expectation remain possible contributors.

Decision

I consider the experiment a success and am filing it as helpful. The endpoint was smoother movement and reduced clicking; structural cartilage healing was not measured.